Pricing Log in Create free account
Friday 6 November 2026 Export ARWR’s income statement to Excel — free account

Arrowhead Pharmaceuticals, Inc.

ARWR Healthcare Biotechnology

Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.

Revenue
+171.0%
EPS
−7.94%
Free cash flow
−15.4%
Total debt
+259.5%

Quarter to June 2026, against a year earlier

58.23 0.77 +1.34%
Market cap
$8.1B
P/E
0.0×
Fwd P/E
−16.6×
Dividend yield
—
F-score
5/9
Altman Z
2.98
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Arrowhead Pharmaceuticals, Inc. (ARWR) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Nov 4, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation
8-K Aug 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 23 added · 6 removed · 32 modified
P2I1A: no material changes, the filing says
8-K Jun 12, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits Officer departure
10-Q Mar 31, 2026
8-K May 7, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Mar 19, 2026 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
10-Q Dec 31, 2025
8-K Feb 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Jan 7, 2026 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 6, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Sep 30, 2025 1: 35 added · 41 removed · 114 modified
1A: 19 added · 6 removed · 132 modified
7: 34 added · 29 removed · 41 modified
8-K Nov 25, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 18, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 11, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 10, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 2, 2025 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K Aug 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K May 12, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Feb 10, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Dec 31, 2024
8-K Nov 26, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Sep 30, 2024
8-K Aug 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K May 9, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 29, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.